Effect of syntocinone (active ingredient: oxytocin) on neuronal processing of alcohol stimuli

Not Applicable

• Conditions: Alcohol Use Disorder (DSM-5)

• Registration Number: DRKS00026218
• Lead Sponsor: Zentralinstitut für Seelische Gesundheit

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-09-08
• Study Completion: 2023-05-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

Age between 18 and 65 years; ability to give fully informed consent and to undergo functional magnetic resonance imaging; written informed consent; diagnosis of alcohol use disorder according to DSM-5 (min. 2 AUD criteria).

Exclusion Criteria

Pregnancy or lactation; presence of severe heart disease or long QT syndrome; participants < 18 or > 65 years of age; psychosis or other severe psychiatric disorder; severe internistic and neurological comorbidities; use of psychotropic medication other than antidepressants from the group of serotonin reuptake inhibitors (SSRI) or mirtazapine and of pipamperone; Current drug abuse of amphetamines, opiates, benzodiazepines, and cocaine (urine drug screening); Contraindication to functional magnetic resonance imaging.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
cue-reactivity (fMRI)

Secondary Outcome Measures

Name	Time	Method
Alcohol Urge Questionnaire (repeated measurement; sum scores)<br>depressive symptoms (BDI-II sum score)<br>anxiety (STAI sum score)<br>perceived stress (Perceived Stress Scale sum score)<br>personality (NEO-FFI sum score, only compared between subjects)<br><br>biomaterials <br>- oxytocin plasma level<br>- cortisol level (saliva)<br>- inflammation markers<br>- appetite- and volume markers (leptine, ghrelin)<br>